Navigation Links
Madhya Pradesh to Raise the Retirement Age of Specialist Medicos'

Madhya Pradesh may raise the retirement age of medical specialists and provide special allowance to doctors posted in interior areas// in order to provide due healthcare to people.

"Providing better health and medical services to people is a priority of the state government and for this the government will provide basic facilities to doctors posted in rural areas. If needed, special allowance will also be provided to them," Chief Minister Shivraj Singh Chouhan said.

Speaking at a seminar on 'Tuberculosis and lung diseases' here, he said the government would consider raising the retirement age of specialists due to their shortage and lack of health care facilities in rural areas.

Chouhan said his government was emphasising on running full-fledged district hospitals at all district towns, community health centres in blocks and in posting doctors in interior areas.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Madhya Pradesh Cops to attend Yoga classes to reduce stress and weight
2. Madhya Pradesh: Blood Transfusion Infects 136 Individuals With HIV
3. Bird Flu Fear Grips Madhya Pradesh
4. Bird Flu Raises Its Ugly Head in Jalgaon and Madhya Pradesh
5. Bird Flu Sample Tests Positive In Madhya Pradesh
6. Bird Flu Spreading Towards Madhya Pradesh
7. Sati Raises its Ugly Head in Madhya Pradesh
8. More Culling in Madhya Pradesh Due to Bird Flu Fears
9. Anthrax Kills 50 Cattle in Madhya Pradesh
10. Madhya Pradesh Shows Indifferent Attitude Towards Infant Mortality
11. Madhya Pradesh To Concentrate On Better Rural Hygiene
Post Your Comments:
(Date:7/25/2008)... This donation will be used to facilitate...ices for children , Haupp...ivci.com ), a leading integrator of enterprise co...deo conferencing, telepresence, audio visual integ...ed today that it has donated video conferencing eq...
(Date:7/24/2008)...EM, N.C. Researchers at Wake Forest University B...ng clinical belief that the hepatitis C virus slow... itself after HIV patients are treated with a comb...atitis C (HCV) infection is more serious in HIV-in...rding to the Centers for Disease Control. Intraven...
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Speaker Nancy P...g in support of the Tom Lantos,and Henry J. Hyde G...nd,Malaria Reauthorization Act of 2008. The bill, ...e this evening by a vote of 303 to 115 and will no...Today the House took an historic vote to pass land...
(Date:7/24/2008)...olo., July 24 /PRNewswire/ -- An Arapahoe County D...ic company what will likely,amount to more than $1...tween the minority shareholders of Inverness-based...-based private company PR Pharmaceuticals, Inc.,Th...dent, Steven Howe, and,CEO, Dr. Patrick Bols, brea...
Breaking Medicine News(10 mins):Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2Health News:Jury Award to Englewood Company to Total More Than $1 Million for Breach of Fiduciary Duties in Shareholder Class Action Case 2
... fish at least once a month can minimise the risk ...d researchers. Around 607 participants developed...dy involving more than 43,005 men aged 39 to 76. I...clot that blocks the blood vessel supplying the br...
...ug fluvoxamine has been found by researchers to be...od shifts in women with borderline personality dis...renic, non-bipolar women with borderline// persona...onducted by researchers from various universities ...
...evious research evidence that HRT could reduce ris...n reversed by a recent study of 1000 women of ages...r in the United Kingdom.The aim of the study was t...and progesterone reduced the risk of future heart ...
...chers in there study are trying to observe why su...e but studies are ongoing. It's long been known th...and other mental functions after an operation// - ...function (POCD).Often relatives will say that the ...
Other Medicine News:
(Date:7/22/2008)...cuss Development Plan Completed Successfully, DUB...arin Corporation,plc (NASDAQ: AMRN ) today announ...t the U.S. Food and Drug Administration (FDA) to d...he treatment of,hypertriglyceridemia. Following th...e 3 with AMR101 in hypertriglyceridemia., Dr. Dec...
(Date:7/22/2008)...l Stress the Importance to Patients of Passing a ...ay, RICHMOND, Va., July 22 /PRNewswire-FirstCall/...ollow-on biologics and biopharmaceuticals, today,a..., will present at a,Congressional briefing on Frid...d for establishing an approval pathway for follow-...
(Date:7/22/2008)...ative Laser Lipolysis Technology in the European ...ass., July 22 /- Cynosure, ...ufacturer of a broad array of,light-based aestheti...Mark,for Smartlipo MPX(TM), the company,s high-pow...uefy fat and tighten skin through collagen,remodel...
(Date:7/21/2008)...s on use of Zevalin as consolidation therapy after...ents with follicular ...l/ -- Cell Therapeutics, Inc.,(CTI) (Nasdaq and MT...duled,a meeting with the U.S. Food and Drug Admini...lity of filing a supplemental Biologics License,Ap...
Breaking Medicine Technology:Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation 2Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation 3CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 2CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 3CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 4Halozyme Therapeutics Presents Pre Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association 1791 1Halozyme Therapeutics Presents Pre Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association 1791 2Halozyme Therapeutics Presents Pre Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association 1791 3Halozyme Therapeutics Presents Pre Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association 1791 4New HPV Vaccine Promising in Mice 16809 1New HPV Vaccine Promising in Mice 16809 2New HPV Vaccine Promising in Mice 16809 3Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 1Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 2Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 3Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 4Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 5Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 6Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 7Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 8Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 9AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4593 1AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4593 2AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4593 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4593 4
... 5, 2007 - MIV Therapeutics Inc.,(OTCBB:MIVT) (FWB...ompatible coatings and advanced drug delivery syst...e medical devices, today,announced that a recent C... Biosync Scientific,s certified bare metal stent p...mpany,s polymer-free drug,delivery system met crit...
...RNewswire/ -- Nereus,Pharmaceuticals, Inc., a pion...microbial sources, and its collaborators will pres...ng its cancer drug,candidates at the American Asso...Angeles April 14-18. Four posters and two,minisymp...tumor,activity in several tumor models for three N...
Other Medicine Technology:MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 2MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 3MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 4Nereus Pharmaceuticals to Present Data at the American Association,for Cancer Research 2007 Annual Meeting 2Nereus Pharmaceuticals to Present Data at the American Association,for Cancer Research 2007 Annual Meeting 3Nereus Pharmaceuticals to Present Data at the American Association,for Cancer Research 2007 Annual Meeting 4Nereus Pharmaceuticals to Present Data at the American Association,for Cancer Research 2007 Annual Meeting 5
Stainless Steel
2 Sided Pivoted Closed Ring Design,Pointed And Smooth Sides; in stainless steel.
The e.cam single-detector system offers general purpose scanning flexibility with unrestricted access for gurneys and wheelchairs. This cost-effective system features a clinically versatile open gant
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM
Medicine Products: